Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2022 | $6.00 | Buy | H.C. Wainwright |
| 10/10/2022 | $9.00 → $2.00 | Buy → Hold | Stifel |
| 8/18/2022 | Overweight | Wells Fargo | |
| 3/31/2022 | $7.00 | Overweight | Piper Sandler |
| 2/23/2022 | $12.00 | Overweight | Cantor Fitzgerald |
| 10/21/2021 | $10.00 | Buy | Truist |
| 10/12/2021 | $13.00 → $12.00 | Outperform | SVB Leerink |
| 9/30/2021 | $12.00 | Buy | Stifel |
MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois. Details of the poster presentation are as follows: Title: Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Authors: Antho
MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 at 2:20 p.m. Eastern Daylight Time. A live webcast of the presentation will be accessible on Affimed's website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed's website for 30 days after the c
In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting confirmatory scan) and a disease control rate (DCR) of 76%; tumor shrinkage was observed in 48% of patients; preliminary median progression free survival (PFS) is 5.6 months and 36% of patients remain on treatmentIn 17 heavily pretreated NSCLC EGFR mutant (EGFRmut) patients the combination shows an ORR of 24% and a DCR of 71%; tumor shrinkage was observed in 41% of patients; median PFS is 5.6 months and 5 patients (29%) are on treatment for over 10 monthsBoth cohorts demonstrated a well-manageable sid
H.C. Wainwright initiated coverage of Affimed Therapeutics with a rating of Buy and set a new price target of $6.00
Stifel downgraded Affimed Therapeutics from Buy to Hold and set a new price target of $2.00 from $9.00 previously
Wells Fargo resumed coverage of Affimed Therapeutics with a rating of Overweight
SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)
6-K - Affimed N.V. (0001608390) (Filer)
6-K - Affimed N.V. (0001608390) (Filer)
MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO). Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. He has a proven track record in successfully advancing the development of novel oncology assets, rais
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort's appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. "We are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board," said Dr. Thomas Hecht, Chairman of Affimed's Supervisory Board. "Constanze brings a wealth of legal expertise and a deep understanding of the biotech and he
HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021. "We are pleased to welcome Uta to Affimed's Supervisory Board," said Dr. Thomas Hecht, Chairman of the Supervisory Board. "Uta brings unique and very deep and extensive executive experience in the life sciences industry. With over 20 years of leadership roles in driving higher busine
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/in
AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call on December 17, 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101): Updated clinical data from the four cohorts of the run-in phase to be presented in a poster session at ASH 2024.AFM28 monotherapy phase 1 dose-escalation study: Updated clinical data to be presented at an oral presentation at ASH 2024.Cash runway into Q4 2025: As of September 30, 2024, cash, cash equivalents and investments were €24.1 million. Based on operating and financial plans cash-runway projected
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r
SC 13G - Affimed N.V. (0001608390) (Subject)
SC 13G/A - Affimed N.V. (0001608390) (Subject)
SC 13G/A - Affimed N.V. (0001608390) (Subject)